Click for best price
Recombinant Erythropoietin Drugs Market Size, Share 2022
Market Analysis and Insights: Global Recombinant Erythropoietin Drugs Market
The global Recombinant Erythropoietin Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Erythropoietin Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Erythropoietin Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Erythropoietin Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Erythropoietin Drugs market.
Global Recombinant Erythropoietin Drugs Scope and Market Size
Recombinant Erythropoietin Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Erythropoietin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Recombinant Erythropoietin Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Recombinant Erythropoietin Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Recombinant Erythropoietin Drugs, with price, sales, revenue, and global market share of Recombinant Erythropoietin Drugs from 2019 to 2022.
Chapter 3, the Recombinant Erythropoietin Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Erythropoietin Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Recombinant Erythropoietin Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Erythropoietin Drugs.
Chapter 13, 14, and 15, to describe Recombinant Erythropoietin Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Recombinant Erythropoietin Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Recombinant Erythropoietin Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
100 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Recombinant Erythropoietin Drugs Product Introduction
1.2 Global Recombinant Erythropoietin Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Recombinant Erythropoietin Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Recombinant Erythropoietin Drugs Sales in Volume for the Year 2017-2028
1.3 United States Recombinant Erythropoietin Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Recombinant Erythropoietin Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Recombinant Erythropoietin Drugs Sales in Volume for the Year 2017-2028
1.4 Recombinant Erythropoietin Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Recombinant Erythropoietin Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Recombinant Erythropoietin Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Recombinant Erythropoietin Drugs Market Dynamics
1.5.1 Recombinant Erythropoietin Drugs Industry Trends
1.5.2 Recombinant Erythropoietin Drugs Market Drivers
1.5.3 Recombinant Erythropoietin Drugs Market Challenges
1.5.4 Recombinant Erythropoietin Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Recombinant Erythropoietin Drugs Market Segment by Type
2.1.1 rhEPO
2.1.2 Erythropoiesis-Stimulating Agents (ESA)
2.2 Global Recombinant Erythropoietin Drugs Market Size by Type
2.2.1 Global Recombinant Erythropoietin Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Recombinant Erythropoietin Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Recombinant Erythropoietin Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Recombinant Erythropoietin Drugs Market Size by Type
2.3.1 United States Recombinant Erythropoietin Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Recombinant Erythropoietin Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Recombinant Erythropoietin Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Recombinant Erythropoietin Drugs Market Segment by Application
3.1.1 Chronic Kidney Disease
3.1.2 Cancer Related Anemia
3.1.3 Others
3.2 Global Recombinant Erythropoietin Drugs Market Size by Application
3.2.1 Global Recombinant Erythropoietin Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Recombinant Erythropoietin Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Recombinant Erythropoietin Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Recombinant Erythropoietin Drugs Market Size by Application
3.3.1 United States Recombinant Erythropoietin Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Recombinant Erythropoietin Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Recombinant Erythropoietin Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Recombinant Erythropoietin Drugs Competitor Landscape by Company
4.1 Global Recombinant Erythropoietin Drugs Market Size by Company
4.1.1 Top Global Recombinant Erythropoietin Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Recombinant Erythropoietin Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Recombinant Erythropoietin Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Recombinant Erythropoietin Drugs Price by Manufacturer (2017-2022)
4.2 Global Recombinant Erythropoietin Drugs Concentration Ratio (CR)
4.2.1 Recombinant Erythropoietin Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Recombinant Erythropoietin Drugs in 2021
4.2.3 Global Recombinant Erythropoietin Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Recombinant Erythropoietin Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Recombinant Erythropoietin Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Recombinant Erythropoietin Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Recombinant Erythropoietin Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Recombinant Erythropoietin Drugs Market Size by Company
4.5.1 Top Recombinant Erythropoietin Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Recombinant Erythropoietin Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Recombinant Erythropoietin Drugs Sales by Players (2020, 2021 & 2022)
5 Global Recombinant Erythropoietin Drugs Market Size by Region
5.1 Global Recombinant Erythropoietin Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Recombinant Erythropoietin Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Recombinant Erythropoietin Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Recombinant Erythropoietin Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Recombinant Erythropoietin Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Recombinant Erythropoietin Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Recombinant Erythropoietin Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Recombinant Erythropoietin Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Recombinant Erythropoietin Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Recombinant Erythropoietin Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Recombinant Erythropoietin Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Recombinant Erythropoietin Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Recombinant Erythropoietin Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Recombinant Erythropoietin Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Recombinant Erythropoietin Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Recombinant Erythropoietin Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Recombinant Erythropoietin Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Corporation Information
7.1.2 Amgen Description and Business Overview
7.1.3 Amgen Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Amgen Recombinant Erythropoietin Drugs Products Offered
7.1.5 Amgen Recent Development
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporation Information
7.2.2 Johnson & Johnson Description and Business Overview
7.2.3 Johnson & Johnson Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Johnson & Johnson Recombinant Erythropoietin Drugs Products Offered
7.2.5 Johnson & Johnson Recent Development
7.3 Kyowa Hakko Kirin
7.3.1 Kyowa Hakko Kirin Corporation Information
7.3.2 Kyowa Hakko Kirin Description and Business Overview
7.3.3 Kyowa Hakko Kirin Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Kyowa Hakko Kirin Recombinant Erythropoietin Drugs Products Offered
7.3.5 Kyowa Hakko Kirin Recent Development
7.4 Roche
7.4.1 Roche Corporation Information
7.4.2 Roche Description and Business Overview
7.4.3 Roche Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Roche Recombinant Erythropoietin Drugs Products Offered
7.4.5 Roche Recent Development
7.5 3SBio Group
7.5.1 3SBio Group Corporation Information
7.5.2 3SBio Group Description and Business Overview
7.5.3 3SBio Group Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 3SBio Group Recombinant Erythropoietin Drugs Products Offered
7.5.5 3SBio Group Recent Development
7.6 Celltrion, Inc
7.6.1 Celltrion, Inc Corporation Information
7.6.2 Celltrion, Inc Description and Business Overview
7.6.3 Celltrion, Inc Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Celltrion, Inc Recombinant Erythropoietin Drugs Products Offered
7.6.5 Celltrion, Inc Recent Development
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Corporation Information
7.7.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
7.7.3 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Products Offered
7.7.5 Teva Pharmaceutical Industries Ltd Recent Development
7.8 F. Hoffmann-La Roche Ltd
7.8.1 F. Hoffmann-La Roche Ltd Corporation Information
7.8.2 F. Hoffmann-La Roche Ltd Description and Business Overview
7.8.3 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Drugs Products Offered
7.8.5 F. Hoffmann-La Roche Ltd Recent Development
7.9 LG Life Sciences Ltd
7.9.1 LG Life Sciences Ltd Corporation Information
7.9.2 LG Life Sciences Ltd Description and Business Overview
7.9.3 LG Life Sciences Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 LG Life Sciences Ltd Recombinant Erythropoietin Drugs Products Offered
7.9.5 LG Life Sciences Ltd Recent Development
7.10 Biocon Limited
7.10.1 Biocon Limited Corporation Information
7.10.2 Biocon Limited Description and Business Overview
7.10.3 Biocon Limited Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Biocon Limited Recombinant Erythropoietin Drugs Products Offered
7.10.5 Biocon Limited Recent Development
7.11 Intas Pharmaceuticals Ltd
7.11.1 Intas Pharmaceuticals Ltd Corporation Information
7.11.2 Intas Pharmaceuticals Ltd Description and Business Overview
7.11.3 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Drugs Products Offered
7.11.5 Intas Pharmaceuticals Ltd Recent Development
7.12 Sun Pharmaceutical Industries Ltd
7.12.1 Sun Pharmaceutical Industries Ltd Corporation Information
7.12.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
7.12.3 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Sun Pharmaceutical Industries Ltd Products Offered
7.12.5 Sun Pharmaceutical Industries Ltd Recent Development
7.13 Dr. Reddy's Laboratories Ltd
7.13.1 Dr. Reddy's Laboratories Ltd Corporation Information
7.13.2 Dr. Reddy's Laboratories Ltd Description and Business Overview
7.13.3 Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Dr. Reddy's Laboratories Ltd Products Offered
7.13.5 Dr. Reddy's Laboratories Ltd Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Recombinant Erythropoietin Drugs Industry Chain Analysis
8.2 Recombinant Erythropoietin Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Recombinant Erythropoietin Drugs Distributors
8.3 Recombinant Erythropoietin Drugs Production Mode & Process
8.4 Recombinant Erythropoietin Drugs Sales and Marketing
8.4.1 Recombinant Erythropoietin Drugs Sales Channels
8.4.2 Recombinant Erythropoietin Drugs Distributors
8.5 Recombinant Erythropoietin Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Recombinant Erythropoietin Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Recombinant Erythropoietin Drugs Market Trends
Table 3. Recombinant Erythropoietin Drugs Market Drivers
Table 4. Recombinant Erythropoietin Drugs Market Challenges
Table 5. Recombinant Erythropoietin Drugs Market Restraints
Table 6. Global Recombinant Erythropoietin Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Recombinant Erythropoietin Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Recombinant Erythropoietin Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Recombinant Erythropoietin Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Recombinant Erythropoietin Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Recombinant Erythropoietin Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Recombinant Erythropoietin Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Recombinant Erythropoietin Drugs Sales by Manufacturer, (KG), 2017-2022
Table 14. Global Recombinant Erythropoietin Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Recombinant Erythropoietin Drugs Price by Manufacturer (2017-2022) & (USD/g)
Table 16. Global Recombinant Erythropoietin Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Recombinant Erythropoietin Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Erythropoietin Drugs as of 2021)
Table 18. Top Players of Recombinant Erythropoietin Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Recombinant Erythropoietin Drugs Product Type
Table 20. Date of International Manufacturers Enter into Recombinant Erythropoietin Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Recombinant Erythropoietin Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Recombinant Erythropoietin Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Recombinant Erythropoietin Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Recombinant Erythropoietin Drugs Sales by Players, (KG), 2020, 2021 & 2022
Table 26. United States Recombinant Erythropoietin Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Recombinant Erythropoietin Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Recombinant Erythropoietin Drugs Sales in Volume by Region (2017-2022) & (KG)
Table 29. Global Recombinant Erythropoietin Drugs Sales in Volume Forecast by Region (2023-2028) & (KG)
Table 30. Global Recombinant Erythropoietin Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Recombinant Erythropoietin Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Recombinant Erythropoietin Drugs Sales in Volume by Country (2017-2028) & (KG)
Table 33. North America Recombinant Erythropoietin Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Recombinant Erythropoietin Drugs Sales in Volume by Region (2017-2028) & (KG)
Table 35. Asia Pacific Recombinant Erythropoietin Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Recombinant Erythropoietin Drugs Sales in Volume by Country (2017-2028) & (KG)
Table 37. Europe Recombinant Erythropoietin Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Recombinant Erythropoietin Drugs Sales in Volume by Country (2017-2028) & (KG)
Table 39. Latin Americaa Recombinant Erythropoietin Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Recombinant Erythropoietin Drugs Sales in Volume by Country (2017-2028) & (KG)
Table 41. Middle East and Africa Recombinant Erythropoietin Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Amgen Corporation Information
Table 43. Amgen Description and Business Overview
Table 44. Amgen Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 45. Amgen Recombinant Erythropoietin Drugs Product
Table 46. Amgen Recent Development
Table 47. Johnson & Johnson Corporation Information
Table 48. Johnson & Johnson Description and Business Overview
Table 49. Johnson & Johnson Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 50. Johnson & Johnson Product
Table 51. Johnson & Johnson Recent Development
Table 52. Kyowa Hakko Kirin Corporation Information
Table 53. Kyowa Hakko Kirin Description and Business Overview
Table 54. Kyowa Hakko Kirin Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 55. Kyowa Hakko Kirin Product
Table 56. Kyowa Hakko Kirin Recent Development
Table 57. Roche Corporation Information
Table 58. Roche Description and Business Overview
Table 59. Roche Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 60. Roche Product
Table 61. Roche Recent Development
Table 62. 3SBio Group Corporation Information
Table 63. 3SBio Group Description and Business Overview
Table 64. 3SBio Group Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 65. 3SBio Group Product
Table 66. 3SBio Group Recent Development
Table 67. Celltrion, Inc Corporation Information
Table 68. Celltrion, Inc Description and Business Overview
Table 69. Celltrion, Inc Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 70. Celltrion, Inc Product
Table 71. Celltrion, Inc Recent Development
Table 72. Teva Pharmaceutical Industries Ltd Corporation Information
Table 73. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 74. Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 75. Teva Pharmaceutical Industries Ltd Product
Table 76. Teva Pharmaceutical Industries Ltd Recent Development
Table 77. F. Hoffmann-La Roche Ltd Corporation Information
Table 78. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 79. F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 80. F. Hoffmann-La Roche Ltd Product
Table 81. F. Hoffmann-La Roche Ltd Recent Development
Table 82. LG Life Sciences Ltd Corporation Information
Table 83. LG Life Sciences Ltd Description and Business Overview
Table 84. LG Life Sciences Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 85. LG Life Sciences Ltd Product
Table 86. LG Life Sciences Ltd Recent Development
Table 87. Biocon Limited Corporation Information
Table 88. Biocon Limited Description and Business Overview
Table 89. Biocon Limited Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 90. Biocon Limited Product
Table 91. Biocon Limited Recent Development
Table 92. Intas Pharmaceuticals Ltd Corporation Information
Table 93. Intas Pharmaceuticals Ltd Description and Business Overview
Table 94. Intas Pharmaceuticals Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 95. Intas Pharmaceuticals Ltd Product
Table 96. Intas Pharmaceuticals Ltd Recent Development
Table 97. Sun Pharmaceutical Industries Ltd Corporation Information
Table 98. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 99. Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 100. Sun Pharmaceutical Industries Ltd Product
Table 101. Sun Pharmaceutical Industries Ltd Recent Development
Table 102. Dr. Reddy's Laboratories Ltd Corporation Information
Table 103. Dr. Reddy's Laboratories Ltd Description and Business Overview
Table 104. Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Drugs Sales (KG), Revenue (US$ Million), Price (USD/g) and Gross Margin (2017-2022)
Table 105. Dr. Reddy's Laboratories Ltd Product
Table 106. Dr. Reddy's Laboratories Ltd Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Recombinant Erythropoietin Drugs Customers List
Table 110. Recombinant Erythropoietin Drugs Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Erythropoietin Drugs Product Picture
Figure 2. Global Recombinant Erythropoietin Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Recombinant Erythropoietin Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Recombinant Erythropoietin Drugs Sales 2017-2028 (KG)
Figure 5. United States Recombinant Erythropoietin Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Recombinant Erythropoietin Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Recombinant Erythropoietin Drugs Sales 2017-2028 (KG)
Figure 8. United States Recombinant Erythropoietin Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Recombinant Erythropoietin Drugs Market Share in Global, in Volume (KG) 2017-2028
Figure 10. Recombinant Erythropoietin Drugs Report Years Considered
Figure 11. Product Picture of rhEPO
Figure 12. Product Picture of Erythropoiesis-Stimulating Agents (ESA)
Figure 13. Global Recombinant Erythropoietin Drugs Market Share by Type in 2022 & 2028
Figure 14. Global Recombinant Erythropoietin Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Recombinant Erythropoietin Drugs Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Recombinant Erythropoietin Drugs Sales by Type (2017-2028) & (KG)
Figure 17. Global Recombinant Erythropoietin Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Recombinant Erythropoietin Drugs Price by Type (2017-2028) & (USD/g)
Figure 19. United States Recombinant Erythropoietin Drugs Market Share by Type in 2022 & 2028
Figure 20. United States Recombinant Erythropoietin Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Recombinant Erythropoietin Drugs Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Recombinant Erythropoietin Drugs Sales by Type (2017-2028) & (KG)
Figure 23. United States Recombinant Erythropoietin Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Recombinant Erythropoietin Drugs Price by Type (2017-2028) & (USD/g)
Figure 25. Product Picture of Chronic Kidney Disease
Figure 26. Product Picture of Cancer Related Anemia
Figure 27. Product Picture of Others
Figure 28. Global Recombinant Erythropoietin Drugs Market Share by Application in 2022 & 2028
Figure 29. Global Recombinant Erythropoietin Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 30. Global Recombinant Erythropoietin Drugs Sales Market Share in Value by Application (2017-2028)
Figure 31. Global Recombinant Erythropoietin Drugs Sales by Application (2017-2028) & (KG)
Figure 32. Global Recombinant Erythropoietin Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 33. Global Recombinant Erythropoietin Drugs Price by Application (2017-2028) & (USD/g)
Figure 34. United States Recombinant Erythropoietin Drugs Market Share by Application in 2022 & 2028
Figure 35. United States Recombinant Erythropoietin Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 36. United States Recombinant Erythropoietin Drugs Sales Market Share in Value by Application (2017-2028)
Figure 37. United States Recombinant Erythropoietin Drugs Sales by Application (2017-2028) & (KG)
Figure 38. United States Recombinant Erythropoietin Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 39. United States Recombinant Erythropoietin Drugs Price by Application (2017-2028) & (USD/g)
Figure 40. North America Recombinant Erythropoietin Drugs Sales in Volume Growth Rate 2017-2028 (KG)
Figure 41. North America Recombinant Erythropoietin Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 42. U.S. Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Canada Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 44. Europe Recombinant Erythropoietin Drugs Sales in Volume Growth Rate 2017-2028 (KG)
Figure 45. Europe Recombinant Erythropoietin Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. Germany Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. France Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. U.K. Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Italy Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Russia Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Asia-Pacific Recombinant Erythropoietin Drugs Sales in Volume Growth Rate 2017-2028 (KG)
Figure 52. Asia-Pacific Recombinant Erythropoietin Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 53. China Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Japan Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. South Korea Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. India Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Australia Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Taiwan Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Indonesia Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Thailand Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Malaysia Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Philippines Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Latin America Recombinant Erythropoietin Drugs Sales in Volume Growth Rate 2017-2028 (KG)
Figure 64. Latin America Recombinant Erythropoietin Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 65. Mexico Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Brazil Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Argentina Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Middle East & Africa Recombinant Erythropoietin Drugs Sales in Volume Growth Rate 2017-2028 (KG)
Figure 69. Middle East & Africa Recombinant Erythropoietin Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 70. Turkey Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Saudi Arabia Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. U.A.E Recombinant Erythropoietin Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Recombinant Erythropoietin Drugs Value Chain
Figure 74. Recombinant Erythropoietin Drugs Production Process
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
